Konrad J. Kuhn, Author at Cabot Wealth Network

Konrad J. Kuhn

Konrad J. Kuhn is the recipient of the 2011 National Small Public Company Leadership Council Annual Award, and is a co-founder and chairperson of Independent Group Home Living, Inc. (IGHL). As editor and publisher of The KonLin Letter, a subscriber-based monthly published by KonLin Research & Analysis Corp. since 1982, Kuhn is a leading analyst who picks low-priced stocks with significant profit-making potential.

Pulmatrix (PULM)

July 18, 2016|From Wall Street’s Best Investments|by Konrad J. Kuhn|Wall Street's Best Investments

This biopharma’s stock was added to the Russell Microcap Index last month, and its shares are gathering momentum. Pulmatrix (PULM) From The Konlin Letter More than 30 million Americans and 30 million Europeans have a rare disease. Pulmatrix (PULM) is a clinical stage biopharmaceutical company innovative,...
Read More

Pulmatrix, Inc. (PULM)

January 15, 2016|From Wall Street’s Best Investments|by Konrad J. Kuhn|Wall Street's Best Investments

Stonegate Capital Partners just initiated coverage on this biotech company. Pulmatrix, Inc. (PULM) From The Konlin Letter Pulmatrix, Inc. (PULM) is a clinical stage biopharmaceutical company developing innovative inhaled therapies to address serious pulmonary disease. PULM’s proprietary product pipeline is focused on advancing treatments for diseases,...
Read More

The KonLin Letter

From the issue of |by Konrad J. Kuhn|How To Invest

The KonLin Letter is a unique service that recommends five low-priced stock selections each month including a featured stock of the month, and reviews 30 to 35 different small caps while monitoring a broad range of technical indicators for the best possible Market Advice...
Read More

Top Pick: TONIX Pharmaceutical Holdings, Inc. (TNXP)

January 8, 2013|From Wall Street’s Best Investments|by Konrad J. Kuhn|Wall Street's Best Investments

Today’s new Top Pick for 2013 comes from The KonLin Letter Editor Konrad Kuhn, whose research into this Pink Sheets-listed pharmaceutical suggests it has the potential to more than quintuple in price. “Fibromyalgia syndrome (FM) is a common and complex central nervous system condition by...
Read More

Elephant Talk Communications, Inc. (ETAK)